Merrion receives first milestone from Novo Nordisk in oral insulin tie-up
This article was originally published in Scrip
Executive Summary
Merrion Pharmaceuticals of Ireland has received a milestone payment of $2 million from Novo Nordisk following the start of a Phase I trial of the oral insulin analogue NN1952.